Drug Trial Radar · NCT06046391
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Jul 6, 2023
Primary completion
Oct 19, 2023
Study completion Aug 6, 2024
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Allergic rhinitis (AR) affects large population worldwide, the most commonly used medication include anti-histamine, nasal spray and anti-LTRAs inhibitors (leukotriene receptor antagonists), Even after those first-line treatment, there is still a large number of patient (\~20%) are not well/adequately controlled. Anti-IgE antibody has been approved to treat moderate to severe AR by PMDA/Japan in 2020, demonstrating the efficacy of IgE blockade in the treatment of allergic rhinitis. The current study presents a novel anti-IgE antibody (LP-003) with higher affinity to IgE, stronger efficacy and longer half-life.
Conditions
- Seasonal Allergic Rhinitis
Interventions
LP-003 dose 1Biological
Liquid in vial
LP-003 dose 2Biological
Liquid in vial
PlaceboBiological
Liquid in vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean nasal symptom scoreTime frame: peak pollen period(estimated average 4 weeks)
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Beijing Shijitan Hospital
Beijing, Beijing Municipality, China
Dongfang Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Zhengzhou central hospital
Zhengzhou, Henan, China
Changchun University of Chinese Medicine Affiliated Hospital
Changchun, Jilin, China
Tonghua central hospital
Tonghua, Jilin, China
Yan Bian Chao Yi Hospital
Yanbian, Jilin, China
Yanbian University hospital
Yanji, Jilin, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Yinchuan Peoples Hospital
Yinchuan, Ningxia, China
Zibo central hospital
Zibo, Shandong, China
Linfen Peoples Hospital
Linfen, Shanxi, China
Second hospital of Shanxi Medical University University
Taiyuan, Shanxi, China
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Xidian group hospital
Xi’an, Shanxi, China
Tianjin Peoples Hospital
Tianjing, Tianjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.